Edition:
United States

Profile: Sinovac Biotech Ltd (SVA.O)

SVA.O on Nasdaq

6.11USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$6.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,781
52-wk High
$7.16
52-wk Low
$4.38

Sinovac Biotech Ltd. (Sinovac), incorporated on March 1, 1999, is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company is engaged in developing various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

The Company's product, Healive, is an inactivated Hepatitis A vaccine. The hepatitis A virus primarily impacts the liver by causing it to swell and preventing it from functioning properly. Healive is available in different doses for use by both adults (approximately one milliliter per dose) and children (approximately 0.5 milliliter per dose). The Company's product, Bilive, is a combination vaccine formulated with purified inactivated hepatitis A virus antigen and recombinant (yeast) hepatitis B surface antigen. Bilive is available in different doses for use in both adults and children. The Bilive vaccination schedule consists of over three doses. The second dose is administered one month after the first dose and the third dose is administered approximately six months after the first dose. Booster vaccinations are recommended approximately five years after the initial immunization.

The Company's product, Anflu vaccine, is an inactivated split viron influenza vaccine formulated from approximately three split inactivated viron solutions. The Company sells Anflu in Mexico, Guatemala, Mongolia, Philippines, Tajikistan and Bangladesh. The Company's product, Panflu, is an approved vaccine available in China against the H5N1 influenza virus. The vaccine is approved for supply within China to the Chinese national vaccine stockpiling program. The Company's product, Panflu.1, is an approved vaccine against the influenza A H1N1 virus. The Company was granted a production license for mumps vaccine. The Company's split viron pandemic influenza vaccine has been developed in conjunction with its whole viron pandemic influenza vaccine. This product has been developed to address the needs of young children, who may be more susceptible to adverse reactions to whole viron pandemic influenza vaccine than to a split viron vaccine. The Company was granted the production license of split viron pandemic influenza vaccine that is to be used among the teenagers aged from 12 to 17. The Company has over seven granted patents relating to the EV71 vaccine in China. EV71 vaccine primarily targets children from 6 months old to 3 years old, with each child requiring a total of approximately two doses one month apart from another.

Pneumococcal polysaccharide vaccine (PPV) is a vaccine used to prevent streptococcus pneumoniae (pneumococcus) infections, such as pneumonia and septicemia among adults aged approximately 65 or older, adults with serious long-term health problems, smokers and children approximately two years with serious long-term health problems. Its neumococcal conjugate vaccine will primarily target children approximately two years old. The Company has completed the pre-clinical studies of a human vaccine against varicella. Varicella is a contagious infectious disease caused by the varicella-zoster virus (herpesvirus 3, Human). The Company has completed pre-clinical studies and filed clinical trial application for Hepatitis B vaccine. The Company is developing a new generation of its hepatitis A&B combination vaccine based on its individual hepatitis A and B vaccines.

The Company competes with Kunming Institute of Biological Product, Sanofi Pasteur S.A., Merck Sharp & Dohme Corp, GlaxoSmithKline Biologicals, Changchun Institute of Biological Products, Pukang Biological Co., Ltd., Changchun Changsheng Life Sciences Ltd., Hualan Biological Engineering Inc., Aleph Biological Co., Ltd. and China National Biotec Group Co., Ltd.

Company Address

Sinovac Biotech Ltd

39 Shangdi Xi Road, Haidian Dist
BEIJING   BEJ   100085
P: +8610.82890088
F: +8610.62966910

Company Web Links